Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 Life Science Investing
Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics Pharmaceutical Investing
Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX 2-73 for the Treatment of Early Alzheimer’s Disease Biotech Investing
AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency Biotech Investing
Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine Pharmaceutical Investing
Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients Pharmaceutical Investing
